Cristina Santoro

List of Publications by Year
in descending order

98 papers	1,425 citations	394421 19 h-index	377865 34 g-index
98 all docs	98 docs citations	98 times ranked	1623 citing authors

#	Article	IF	Citations
1	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
2	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
3	Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians. Journal of Thrombosis and Thrombolysis, 2022, 53, 934-944.	2.1	3
4	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
5	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. Internal and Emergency Medicine, 2022, 17, 1081-1085.	2.0	2
6	Haemophilia management and treatment: An Italian survey on patientsâ€™, caregiversâ€™ and cliniciansâ€™ point of view. Haemophilia, 2022, 28, 254-263.	2.1	5
7	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
8	(Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition. Biomedicines, 2022, 10, 625.	3.2	0
9	Immune thrombocytopenia management during COVIDâ€19 pandemic: An Italian monocentric experience. EJHaem, 2022, 3, 453-456.	1.0	5
10	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e328-e333.	0.4	0
11	Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. American Journal of Hematology, 2021, 96, 188-198.	4.1	55
12	Immune thrombocytopenia (<scp>ITP</scp>) <scp>World Impact Survey</scp> (<scp>Iâ€WISh</scp>): Impact of <scp>ITP</scp> on healthâ€related quality of life. American Journal of Hematology, 2021, 96, 199-207.	4.1	54
13	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	2.7	3
14	Eltrombopag secondâ€line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission offâ€treatment: results of a phase II, multicentre, prospective study. British Journal of Haematology, 2021, 193, 386-396.	2.5	23
15	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021032.	1.3	17
16	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
17	A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain. , 2021, 41, .		0
18	A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A. Hamostaseologie, 2021, 41, .	1.9	0

#	Article	IF	Citations
19	Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood, 2021, 137, 3127-3136.	1.4	18
20	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5.2	11
21	Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome. Haemophilia, 2021, 27, e667-e674.	2.1	2
22	Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report. Blood Coagulation and Fibrinolysis, 2021, 32, 519-521.	1.0	3
23	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. Journal of Thrombosis and Thrombolysis, 2021, 52, 105-110.	2.1	18
24	Pain assessment and management in Italian Haemophilia Centres. Blood Transfusion, 2021, 19, 335-342.	0.4	8
25	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1
26	Factor XI deficiency and delayed hemorrhages after resection of choroid plexus papilloma: illustrative case. Journal of Neurosurgery Case Lessons, 2021, 2, .	0.3	0
27	Use of edoxaban for the treatment of venous thromboembolism in <scp>HIV</scp>â€infected patients. HIV Medicine, 2020, 21, e7.	2.2	2
28	Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. Blood Reviews, 2020, 41, 100647.	5.7	20
29	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
30	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60Âyears. Thrombosis Research, 2020, 185, 88-95.	1.7	7
31	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	2.1	17
32	Rituximab for treating inhibitors in people with inherited severe hemophilia. The Cochrane Library, 2020, 8, CD010810.	2.8	2
33	ACQUIRED HAEMOPHILIA A: AN INTRIGUING DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020045.	1.3	8
34	A multicenter realâ€life study on anticoagulant treatment with direct oral anticoagulants in patients with <scp>P</scp>hâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E329-E332.	4.1	14
35	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7
36	Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly. Reports, 2020, 3, 3.	0.5	0

#	Article	IF	Citations
37	Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (FanhdiÂ®): experience of a single center. Heliyon, 2020, 6, e03426.	3.2	6
38	Effect of low or high doses of lowâ€molecularâ€weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVIDâ€19. British Journal of Haematology, 2020, 190, e214-e218.	2.5	25
39	Right elbow arthropathy in a patient with severe haemophilia A. British Journal of Haematology, 2020, 190, 484-484.	2.5	0
40	Direct oral anticoagulants in patients with hematologic malignancies. Hematological Oncology, 2020, 38, 589-596.	1.7	8
41	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. Journal of Thrombosis and Thrombolysis, 2020, 49, 426-430.	2.1	11
42	BAY 81â€8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. European Journal of Haematology, 2020, 105, 164-172.	2.2	5
43	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25Âyears by the â€œPh1â€negative Myeloproliferative Neoplasms Latium Groupâ€. European Journal of Haematology, 2020, 105, 335-343.	2.2	8
44	Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. Transfusion and Apheresis Science, 2020, 59, 102903.	1.0	2
45	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
46	ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients. Blood, 2020, 136, 2-3.	1.4	0
47	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. British Journal of Haematology, 2019, 186, e217-e219.	2.5	1
48	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019044.	1.3	16
49	Immune tolerance induction with moroctocogâ€alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with highâ€titre inhibitors: Data from REF.IT Registry. Haemophilia, 2019, 25, 1003-1010.	2.1	2
50	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPOâ€RA. Haemophilia, 2019, 25, e288-e290.	2.1	2
51	Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents. Clinical Case Reports (discontinued), 2019, 7, 689-694.	0.5	2
52	The impact of psychosocial determinants on caregiversâ€™ burden of children with haemophilia (results) Tj ETQq0 0 0 rgBT /Overlock 1	2.1	13
53	The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the) Tj ETQq1 1 0.784314 rgBT /Ove	2.1	16
54	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfusion, 2019, 17, 171-180.	0.4	32

#	Article	IF	Citations
55	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. Leukemia Research, 2018, 69, 18-23.	0.8	2
56	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	2.1	15
57	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). Seminars in Thrombosis and Hemostasis, 2018, 44, 551-560.	2.7	12
58	Alloantibodies and Congenital Bleeding Disorders: New Insights in the Pathogenesis and Management. Seminars in Thrombosis and Hemostasis, 2018, 44, 505-508.	2.7	1
59	Inhibitors in Hemophilia B. Seminars in Thrombosis and Hemostasis, 2018, 44, 578-589.	2.7	47
60	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
61	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). Blood, 2018, 132, 1135-1135.	1.4	3
62	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood, 2018, 132, 3781-3781.	1.4	0
63	Straightforward Transition to Bay 81-8973 Prophylaxis in Patients with Hemophilia A: Prospective Real-World Data from the Taurus Non-Interventional Study Show That Number of Infusions per Week Is Maintained or Reduced. Blood, 2018, 132, 5045-5045.	1.4	0
64	Determinants of Prophylaxis Regimen Choice for Patients with Hemophilia Î‘ Switching to Bay 81-8973: Real World Findings from the Taurus Non-Interventional Study. Blood, 2018, 132, 5023-5023.	1.4	0
65	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. Blood, 2018, 132, 5464-5464.	1.4	0
66	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
67	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Medicine, 2017, 6, 1233-1239.	2.8	9
68	Anticoagulant therapy in patients with Glanzmann's Thrombasthenia: Is it possible?. Haemophilia, 2017, 23, e531-e533.	2.1	1
69	Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case. Clinical Case Reports (discontinued), 2017, 5, 1385-1388.	0.5	5
70	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	1.7	9
71	<scp>TPO</scp>â€<scp>RA</scp>s in <scp>pITP</scp>: description of a case series and analysis of predictive factors for response. European Journal of Haematology, 2017, 98, 242-249.	2.2	14
72	Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts. Seminars in Thrombosis and Hemostasis, 2016, 42, 563-576.	2.7	14

#	Article	IF	Citations
73	Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma. Seminars in Thrombosis and Hemostasis, 2016, 42, 577-582.	2.7	16
74	Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Seminars in Thrombosis and Hemostasis, 2016, 42, 036-041.	2.7	7
75	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 46, 18-25.	0.8	13
76	Healthâ€related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 2016, 91, 995-1001.	4.1	53
77	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology, 2016, 91, 318-321.	4.1	28
78	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. Blood, 2016, 128, 5469-5469.	1.4	0
79	Bleeding phenotype and correlation with factor XI (FXI) activity in congenital <scp>FXI</scp> deficiency: results of a retrospective study from a single centre. Haemophilia, 2015, 21, 496-501.	2.1	58
80	Pharmacokinetics of plasmaâ€derived vs. recombinant <scp>FVIII</scp> concentrates: a comparative study. Haemophilia, 2015, 21, 204-209.	2.1	22
81	Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thrombosis Research, 2015, 136, 168-174.	1.7	18
82	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
83	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. Blood, 2015, 126, 2815-2815.	1.4	0
84	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). Blood, 2015, 126, 4071-4071.	1.4	0
85	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. Blood, 2015, 126, 2122-2122.	1.4	0
86	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. Blood, 2015, 126, 2811-2811.	1.4	4
87	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821.	1.4	1
88	Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety. Acta Haematologica, 2014, 132, 24-29.	1.4	3
89	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52
90	Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A. Seminars in Thrombosis and Hemostasis, 2013, 39, 711-722.	2.7	11

#	Article	IF	Citations
91	Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. Haemophilia, 2012, 18, 200-204.	2.1	8
92	Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven^{Â®}, a factor XI concentrate. Haemophilia, 2011, 17, 777-782.	2.1	15
93	Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT),. Blood, 2011, 118, 3836-3836.	1.4	1
94	Mortality and causes of death in Italian persons with haemophilia, 1990â€“2007. Haemophilia, 2010, 16, 437-446.	2.1	145
95	Prevalence of alloâ€immunization antiâ€HLA and antiâ€integrin Î±IIbÎ²3 in Glanzmann Thromboasthenia patients. Haemophilia, 2010, 16, 805-812.	2.1	43
96	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. International Journal of Hematology, 2009, 90, 486-491.	1.6	2
97	Performance of recalibrated ReFacto^{Â®} laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and oneâ€stage assays after infusion of recalibrated ReFacto^{Â®} (Bâ€domain deleted recombinant factor VIII). Haemophilia, 2009, 15, 779-787.	2.1	19
98	A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica, 2004, 89, 1306-13.	3.5	44